Integrated bioinformatics and functional studies identify CDK9 as a potential prognostic biomarker and therapeutic target in AML
This study demonstrates that CDK9 is a potential prognostic biomarker and therapeutic target in AML. Its involvement in multiple key pathways during AML development and its influence on the tumor immune microenvironment support further exploration of CDK9-targeted therapies to improve AML treatment outcomes.
Authors
- Meng Wang (ORCID: https://orcid.org/0000-0002-1573-0255)
- Pingping Zhang (ORCID: https://orcid.org/0000-0002-7702-6802)
- Zhongyu Li (ORCID: https://orcid.org/0000-0002-9566-5771)
- Yang Xia (ORCID: https://orcid.org/0000-0001-8783-1592)
- Zhibin Xie (ORCID: https://orcid.org/0009-0004-5981-687X)
- Yuanyuan Tan (ORCID: https://orcid.org/0000-0002-1081-664X)
- Yuqing Han (ORCID: https://orcid.org/0009-0005-2446-4939)
- Mengmeng Zhang (ORCID: https://orcid.org/0000-0001-7294-3655)
- Jiajia Li (ORCID: https://orcid.org/0000-0003-0330-4264)
Institutions
- Bengbu Medical College (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1007/s12672-025-02841-4
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00